Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Total U.S. pharmaceutical and biotech revenues for products 5 years after launch from 2007 to 2017
(in billion U.S. dollars)
Total U.S. pharma and biotech product sales 5 years after launch 2007-2017
This statistic depicts the total pharmaceutical and biotech product revenues in the United States of products five years after launch, from 2007 to 2017. In 2010, product revenues in the U.S. totaled 12.5 billion U.S. dollars for products launched 5 years before.

Pharma and biotech products

Newer pharmaceutical and biotechnology products have generated increasingly large amounts of revenues after five years of launch. In 2008, revenues were at 5.6 billion U.S. dollars but had skyrocketed to some 31 billion U.S. dollars in 2017. The average cost of developing a new pharmaceutical or biotech entity has increased from 451 million U.S. dollars in 1991 to some 1.5 billion U.S. dollars in the 2010s. Many companies that had once focused primarily on pharmaceuticals have begun to integrate biotechnology in their research, which has minimized the separation between the two industries.

Pharmaceuticals are most commonly manufactured through chemical synthesis processes while biotechnology pharmaceuticals are products created within living organisms such as bacteria and yeast. Recently, biological drugs have become the most prominent products in the medicinal industry. For example, Humira, otherwise known as adalimumab, was approved in the United States by the Food and Drug Administration (FDA) in 2008. Humira is marketed by AbbVie and is used as an anti-inflammatory drug. It has since become one of the largest grossing medical products in the world, generating about 16 billion U.S. dollars in 2015. In the United States, Humira generated 13.6 billion U.S. dollars in revenue in 2016. Expenditure on biologics is expected to increase to 221 billion U.S. dollars globally by 2017.
Total U.S. pharmaceutical and biotech revenues for products 5 years after launch from 2007 to 2017
(in billion U.S. dollars)
Revenue in billion U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

December 2017

Region

United States

Survey time period

as of November 2017

Supplementary notes

* Values until 2012 were assembled from previous editions of the report.
** Potential total for 2017.

Total U.S. pharma and biotech product sales 5 years after launch 2007-2017
This statistic depicts the total pharmaceutical and biotech product revenues in the United States of products five years after launch, from 2007 to 2017. In 2010, product revenues in the U.S. totaled 12.5 billion U.S. dollars for products launched 5 years before.

Pharma and biotech products

Newer pharmaceutical and biotechnology products have generated increasingly large amounts of revenues after five years of launch. In 2008, revenues were at 5.6 billion U.S. dollars but had skyrocketed to some 31 billion U.S. dollars in 2017. The average cost of developing a new pharmaceutical or biotech entity has increased from 451 million U.S. dollars in 1991 to some 1.5 billion U.S. dollars in the 2010s. Many companies that had once focused primarily on pharmaceuticals have begun to integrate biotechnology in their research, which has minimized the separation between the two industries.

Pharmaceuticals are most commonly manufactured through chemical synthesis processes while biotechnology pharmaceuticals are products created within living organisms such as bacteria and yeast. Recently, biological drugs have become the most prominent products in the medicinal industry. For example, Humira, otherwise known as adalimumab, was approved in the United States by the Food and Drug Administration (FDA) in 2008. Humira is marketed by AbbVie and is used as an anti-inflammatory drug. It has since become one of the largest grossing medical products in the world, generating about 16 billion U.S. dollars in 2015. In the United States, Humira generated 13.6 billion U.S. dollars in revenue in 2016. Expenditure on biologics is expected to increase to 221 billion U.S. dollars globally by 2017.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Biotech industry"
  • Global overview
  • U.S. companies
  • Research & development
  • Products
  • Funding/investment
  • Biotech in agriculture
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.